Skip to main content
Journal cover image

A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group.

Publication ,  Journal Article
Olsen, NJ; Brooks, RH; Cush, JJ; Lipsky, PE; St Clair, EW; Matteson, EL; Gold, KN; Cannon, GW; Jackson, CG; McCune, WJ; Fox, DA; Nelson, B ...
Published in: Arthritis Rheum
July 1996

OBJECTIVE: To evaluate the efficacy of an anti-CD5 ricin-linked immunoconjugate (CD5-IC) in patients with rheumatoid arthritis (RA). METHODS: A total of 104 evaluable patients were enrolled in a multicenter, double-blind, multiple-dose, placebo-controlled study of CD5-IC. RESULTS: Treatment with CD5-IC in doses up to 8 mg/m2/day for 4 days in 1 month failed to produce marked or prolonged T cell depletion and was no more effective than placebo in ameliorating disease manifestations. An unexpectedly high placebo response was observed in 48% of the patients. Adverse events were correlated with the dose of CD5-IC, but the treatment was generally well-tolerated. CONCLUSION: At the doses used in this study, CD5-IC was ineffective for treating RA.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Arthritis Rheum

DOI

ISSN

0004-3591

Publication Date

July 1996

Volume

39

Issue

7

Start / End Page

1102 / 1108

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Ricin
  • Middle Aged
  • Lymphocyte Depletion
  • Immunoconjugates
  • Humans
  • Drug Administration Schedule
  • Double-Blind Method
  • CD5 Antigens
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Olsen, N. J., Brooks, R. H., Cush, J. J., Lipsky, P. E., St Clair, E. W., Matteson, E. L., … Strand, V. (1996). A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum, 39(7), 1102–1108. https://doi.org/10.1002/art.1780390705
Olsen, N. J., R. H. Brooks, J. J. Cush, P. E. Lipsky, E. W. St Clair, E. L. Matteson, K. N. Gold, et al. “A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group.Arthritis Rheum 39, no. 7 (July 1996): 1102–8. https://doi.org/10.1002/art.1780390705.
Olsen NJ, Brooks RH, Cush JJ, Lipsky PE, St Clair EW, Matteson EL, et al. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum. 1996 Jul;39(7):1102–8.
Olsen, N. J., et al. “A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group.Arthritis Rheum, vol. 39, no. 7, July 1996, pp. 1102–08. Pubmed, doi:10.1002/art.1780390705.
Olsen NJ, Brooks RH, Cush JJ, Lipsky PE, St Clair EW, Matteson EL, Gold KN, Cannon GW, Jackson CG, McCune WJ, Fox DA, Nelson B, Lorenz T, Strand V. A double-blind, placebo-controlled study of anti-CD5 immunoconjugate in patients with rheumatoid arthritis. The Xoma RA Investigator Group. Arthritis Rheum. 1996 Jul;39(7):1102–1108.
Journal cover image

Published In

Arthritis Rheum

DOI

ISSN

0004-3591

Publication Date

July 1996

Volume

39

Issue

7

Start / End Page

1102 / 1108

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Ricin
  • Middle Aged
  • Lymphocyte Depletion
  • Immunoconjugates
  • Humans
  • Drug Administration Schedule
  • Double-Blind Method
  • CD5 Antigens